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Mechanisms of vascular maturation 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Chapter 3      
Strategies for therapeutic angiogenesis 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































       



































































































































































































































































































































































































































































































































































































Coordinated co-expression of PDGF-BB 
accelerates stabilization of VEGF164-induced 
vessels in a dose-dependent fashion 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chapter 5      
Adenoviral co-delivery of VEGF164 and 
PDGF-BB induces safe and persistent 
angiogenesis 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































       







































































































































































































































































































































































































































































  Next we defined,	
   for	
   the	
   first	
   time,	
   whether	
   VEGF	
   dose	
   regulates	
   the	
   time-­‐course	
   of	
  vascular	
   stabilization	
   and	
   how	
   PDGF-­‐BB	
   affects	
   stabilization	
   at	
   different	
   VEGF	
   doses.	
  Interestingly,	
   we	
   found	
   that	
   VEGF	
   negatively	
   regulates	
   vascular	
   stabilization	
   in	
   a	
   dose-­‐dependent	
  fashion.	
  In	
  fact,	
  normal	
  capillaries	
  induced	
  by	
  low	
  VEGF	
  levels	
  stabilized	
  faster	
  than	
   similarly	
   normal	
   vessels	
   induced	
   by	
   higher	
   doses	
   at	
   every	
   time	
   point	
   considered.	
  Aberrant	
   vascular	
   structures	
   induced	
   by	
   very	
   high	
   VEGF	
   levels	
   never	
   stabilized.	
  Surprisingly,	
  we	
  found	
  that	
  PDGF-­‐BB	
  accelerated	
  vascular	
  stability	
  only	
  at	
  medium	
  and	
  high	
  VEGF	
  levels,	
  while	
  it	
  did	
  not	
  have	
  significant	
  effects	
  on	
  vessels	
  induced	
  by	
  low	
  VEGF	
  doses.	
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Mechanistically,	
   we	
   found	
   that	
   vascular	
   stabilization	
   is	
   not	
   simply	
   dependent	
   on	
   the	
  presence	
  of	
  pericytes,	
  because	
  normal	
  capillaries	
  induced	
  by	
  different	
  doses	
  of	
  VEGF	
  alone	
  or	
  with	
  PDGF-­‐BB	
  were	
  equally	
  pericyte-­‐covered	
  but	
  stabilized	
  with	
  different	
  time-­‐courses.	
  Therefore,	
  we	
  investigated	
  the	
  regulation	
  of	
  several	
  factors	
  involved	
  in	
  vascular	
  maturation	
  in	
   the	
   different	
   conditions.	
   Intriguingly,	
   we	
   observed	
   a	
   correlation	
   between	
   the	
   trend	
   of	
  expression	
  of	
  TGF-­‐β1	
  and	
  Sema3A	
  and	
  the	
  trend	
  of	
  vascular	
  stabilization	
  at	
  different	
  VEGF	
  and	
  PDGF-­‐BB	
  doses.	
  	
  Sema3A	
  has	
  been	
  recently	
  described	
  to	
  promote	
  vascular	
  stabilization	
  indirectly	
  through	
  the	
   recruitment	
   of	
   a	
   subset	
   of	
   neuropilin-­‐1+	
   (NP1+)-­‐CD11b+	
   bone	
   marrow-­‐derived	
   cells	
  (Zacchigna	
  2008).	
  These	
  cells	
  are	
  thought	
  to	
  exert	
  their	
  stabilizing	
  effect	
  by	
  expressing	
  pro-­‐maturation	
   factors,	
   such	
   as	
   TGF-­‐β1	
   and	
   PDGF-­‐BB.	
   Therefore,	
   as	
   a	
   next	
   step,	
   it	
   will	
   be	
  interesting	
  to	
  determine	
  whether	
  Sema3A	
  and	
  TGF-­‐β1	
  are	
  involved	
  in	
  vascular	
  maturation	
  through	
   molecular	
   mechanisms	
   involving	
   only	
   the	
   cross-­‐talk	
   between	
   endothelium	
   and	
  pericyte	
   or	
   whether	
   their	
   action	
   is	
   mediated	
   through	
   the	
   recruitment	
   of	
   bone-­‐marrow	
  derived	
  myeloid	
  cells.	
   In	
  order	
  to	
  clarify	
  these	
  interactions,	
  we	
  will	
   test	
  whether	
  different	
  VEGF	
   doses,	
   that	
   promote	
   different	
   stabilization	
   kinetics	
   and	
   are	
   associated	
   with	
   a	
  differential	
  regulation	
  of	
  Sema3A	
  and	
  TGF-­‐β1,	
   induce	
  the	
  recruitment	
  of	
  different	
  amount	
  of	
  CD11b+-­‐NP1+positive	
  cells	
  in	
  the	
  injected	
  muscle	
  from	
  the	
  circulation.	
  Furthermore,	
  the	
  flow	
   cytometry	
   isolation	
   of	
   endothelial	
   cells,	
   pericytes	
   and	
   myeloid	
   cells	
   from	
   muscles	
  injected	
  with	
  myoblast	
   expressing	
  different	
  VEGF	
  doses,	
   alone	
   or	
  with	
  PDGF-­‐BB,	
   and	
   the	
  subsequent	
   analysis	
   of	
   their	
   expression	
   of	
   each	
   molecule	
   by	
   qRT-­‐PCR,	
   will	
   allow	
   us	
   to	
  define	
   quantitatively	
   and	
   qualitatively	
   the	
   role	
   of	
   the	
   different	
   cell	
   types	
   in	
   VEGF-­‐dose	
  dependent	
  vascular	
  stabilization.	
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On	
   the	
  other	
  hand,	
  nothing	
   is	
  known	
  regarding	
  a	
  possible	
  direct	
   regulation	
  of	
  Sema3A	
  expression	
  in	
  vascular	
  cells	
  by	
  VEGF,	
  nor	
  its	
  possible	
  dose	
  dependency.	
  Therefore,	
  it	
  will	
  be	
  necessary	
  to	
  investigate	
  the	
  signaling	
  network	
  between	
  VEGF,	
  TGF-­‐β1	
  and	
  Sema3A,	
  as	
  well	
  as	
   its	
  modulation	
   by	
   PDGF-­‐BB,	
   in	
   vitro.	
   In	
   particular,	
   endothelial	
   cells	
  will	
   be	
   stimulated	
  with	
  different	
  doses	
  of	
  VEGF,	
  PDGF-­‐BB	
  or	
  both	
  and	
  the	
  expression	
  of	
  Sema3A	
  and	
  TGF-­‐β1	
  will	
  be	
  monitored.	
  The	
  combination	
  of	
  in	
  vivo,	
  ex	
  vivo	
  and	
  in	
  vitro	
  approaches	
  described	
  above	
  should	
  help	
  elucidating	
  the	
  molecular	
  mechanisms	
  by	
  which	
  VEGF	
  controls	
   the	
  maturation	
  of	
   induced	
  vessels	
   and	
   also	
   clarifying	
   the	
   role	
   of	
   bone	
   marrow-­‐derived	
   cells	
   in	
   the	
   stabilization	
   of	
  VEGF-­‐induced	
  vessels	
  in	
  skeletal	
  muscle.	
  On	
  the	
  basis	
  of	
  results	
  obtained	
   in	
  the	
  previous	
  chapter,	
   in	
  Chapter	
  5	
  we	
  aimed	
  to	
  test	
  whether	
  VEGF	
  and	
  PDGF-­‐BB	
  co-­‐expression	
  from	
  an	
  adenoviral	
  vector	
  might	
  induce	
  safe	
  and	
  persistent	
  angiogenesis	
  in	
  the	
  short	
  frame	
  of	
  expression	
  allowed	
  by	
  this	
  vector.	
  Indeed,	
  we	
  found	
  that	
  PDFG-­‐BB	
  co-­‐expression	
  prevented	
  the	
  formation	
  of	
  aberrant	
  vessels	
  induced	
  by	
  Ad-­‐VEGF	
  and	
  yielded	
  only	
  normal	
  capillaries,	
  when	
  the	
  two	
  factors	
  were	
  expressed	
  from	
  a	
  single	
  bicistronic	
  vector.	
  Furthermore,	
  in	
  an	
  immunocompetent	
  model,	
  in	
  which	
  adenoviral	
  vectors	
   are	
   cleared	
  within	
   10-­‐14	
  days,	
  we	
   found	
   that	
   a	
   proportion	
   of	
   vessels	
   induced	
  by	
  VEGF	
   and	
   PDGF-­‐BB	
   co-­‐expression	
   had	
   successfully	
   stabilized	
   and	
   persisted	
   after	
   the	
  cessation	
  of	
  VEGF	
  expression.	
  Based	
  on	
  this	
  evidence,	
  we	
  conclude	
  that	
  VEGF	
  and	
  PDGF-­‐BB	
  co-­‐expression	
   provides	
   a	
   clinically	
   relevant	
   gene	
   therapy	
   approach	
   for	
   therapeutic	
  angiogenesis.	
  However,	
  although	
  AV	
  can	
  infect	
  a	
  wide	
  range	
  of	
  cells	
  and	
  tissues,	
  adult	
  muscle	
  fibers	
  are	
  significantly	
   less	
   transducible	
   compared	
   to	
   immature	
   or	
   regenerating	
   myofibers	
   (van	
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Deutekom	
  1998).	
  Therefore,	
  adenovirus	
  transduction	
  of	
  normal	
  adult	
  muscle	
   is	
   limited	
  to	
  the	
   damaged	
   and	
   regenerating	
   myofibers	
   around	
   the	
   needle	
   tracks,	
   resulting	
   in	
   rather	
  limited	
   areas	
   of.	
   Therefore,	
   a	
   more	
   effective	
   strategy,	
   could	
   rely	
   on	
   adeno-­‐associated	
  viruses	
   (AAVs)	
   as	
   the	
   delivery	
   vector.	
   AAVs	
   are	
   small	
   vectors	
   that	
   can	
   transduce	
  mature	
  skeletal	
   fibers	
   much	
   more	
   efficiently	
   than	
   adenoviruses,	
   but	
   lead	
   to	
   persistent	
   gene	
  expression	
  due	
  to	
  their	
  low	
  immunogenicity.	
  The	
  use	
  of	
  this	
  vector	
  would	
  allow	
  the	
  testing	
  of	
  the	
  hypothesis	
  that	
  co-­‐expression	
  of	
  VEGF	
  and	
  PDGF-­‐BB,	
  that	
  yield	
  homogeneous,	
  normal	
  and	
  stable	
  angiogenesis	
  despite	
  heterogeneous	
  levels	
  of	
  expression,	
  can	
  be	
  safe	
  even	
  after	
  sustained	
  expression.	
  In	
  fact,	
  continuously	
  growing	
  angioma-­‐like	
  structures	
  are	
  completely	
  prevented	
  and	
  the	
  induced	
  normal	
  capillary	
  networks	
  have	
  been	
  found	
  to	
  be	
  stable	
  over	
  at	
  least	
  several	
  months	
  (Gianni-­‐Barrera,	
  manuscript	
  submitted).	
  In	
   order	
   to	
   translate	
   the	
   proof-­‐of-­‐principle	
   established	
   in	
   this	
   thesis	
   into	
   a	
   clinical	
  application,	
   further	
   work	
   will	
   be	
   necessary	
   to:	
   1)	
   determine	
   the	
   safety	
   and	
   efficacy	
   of	
  coordinated	
  co-­‐expression	
  of	
  VEGF	
  and	
  PDGF-­‐BB	
  in	
  models	
  of	
  hindlimb	
  or	
  cardiac	
  ischemia,	
  where	
   upregulation	
   of	
   endogenous	
   factors	
   may	
   affect	
   the	
   response	
   to	
   the	
   delivered	
  molecules;	
   and	
  2)	
   carefully	
   establish	
   the	
   therapeutic	
  window	
  of	
   different	
   vector	
  doses	
   in	
  clinically	
  reflective	
  large	
  animal	
  models.	
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